News

Embody Advances Biologic Augmentation Market with First-Of-Its-Kind Collagen Implant

Embody, Inc., a privately-held medical device company developing novel collagen-based technologies for soft tissue injury and repair, announced today the expansion and clinical use cases of TAPESTRY® Biointegrative Implant in the U.S. market. TAPESTRY Biointegrative Implant is the first collagen-based implant with a bioengineered micro-architecture and biostimulative, highly organized type I collagen chemistry specifically designed for the management and protection of tendon injuries. The unique combination of the collagen chemistry and structural integrity provides unparalleled clinical utility and sizing across a broad range of tendon applications including, but not limited to, foot and ankle, knee, and shoulder procedures.

“Catastrophic failure and clinical dysfunction associated with poor subscapularis tendon healing rates following shoulder arthroplasty leads to suboptimal functional outcomes and costly re-operations for our patients,” said Amit Nathani, MD, an Orthopaedic Surgeon and Shoulder Specialist in Santa Barbara, California. “TAPESTRY combines the benefits of collagen-based chemistry with unique sizing, hydrophilicity, and handling characteristics appropriate to augment total shoulder procedures, offering the potential to enhance healing and reduce soft tissue failures.”

“There is a strong clinical need for a better solution to treat tendon injury of the foot & ankle,” said Alan Ng, DPM, FACFAS, at Advanced Orthopedic & Sports Medicine Specialists in Denver, CO. “The TAPESTRY implant is unlike anything else I have used in its ability to form new, dense collagenous tissue at the site of the implantation combined with its superior handling and sizing make it ideal for a variety of challenging tendon procedures including Achilles and paroneal tendons.”

“Following the initial surgical procedures with TAPESTRY, we are seeing continued use and expanded interest across a wide range of demanding tendon applications including subscapularis, patellar, peroneal and Achilles tendons where formative products have lacked the combination of handling, structural integrity, and a biostimulative chemistry,” said Jeff Conroy, CEO of Embody. “We continue to expand our range of sizes and shapes to rapidly accommodate every surgeon’s need.”

Recent News

03/28/2024

ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases,  announces that the company will be utilizing the preclinical services program offered by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate RLS-0071 as a medical countermeasure

03/28/2024

AMPEL BioSolutions’ Lupus Test Launches to Predict Flares & Drug Targets

AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus.  Revealed in the peer-reviewed journal Genome Medicine and being made available to patients through a US follow-on study, the LuGENE® blood test forecasts patient flares and drug targets from gene expression utilizing predictive AI. The LuGENE® lab test is now launching at

03/27/2024

Shaping Tomorrow’s Innovators: LifeNet Health’s Educational Partnership Ignites Student Passion in Life Science

LifeNet Health, a global leader in regenerative medicine, recently collaborated with AP biology students at Landstown High School to offer hands‐on learning experiences with human tissue and cellular solutions. This initiative is part of the Life Sciences Virginia pilot program, which aims to foster interest in life science careers among students and cultivate a talent